<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="X-UA-Compatible" content="ie=edge" />
    <!-- Site title -->
    <title>Clinical Trial Experience – Siklos® (hydroxyurea) - Siklos® HCP</title>
    <!-- Bootstrap css -->
    <link rel="stylesheet" href="assets/css/bootstrap.min.css" />
    <!-- owl css -->
    <link rel="stylesheet" href="assets/css/owl.carousel.min.css" />
    <!-- Main Style css -->
    <link rel="stylesheet" href="assets/css/style.css" />
    <!-- Responsive css -->
    <link rel="stylesheet" href="assets/css/responsive.css" />
    <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
      new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
      j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
      'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
      })(window,document,'script','dataLayer','GTM-TKPNPZ5');
    </script>
    <!-- End Google Tag Manager -->
  </head>
  <body>
    <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-TKPNPZ5"
      height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->
    <!-- Header Start -->
    <div class="header">
      <div class="container">
        <div class="row align-items-center">
          <div class="col-lg-2">
            <a href="index.html" class="logo">
            <img src="assets/img/osphena-logo.svg" alt="">
            </a>
          </div>
          <div class="col-lg-8">
            <div class="top-links">
              <p><a href="https://files.duchesnay.com/duchesnay-usa/osphena/osphena-prescribing-information.pdf" target="_blank">Prescribing Information</a></p>
              <p><strong>For U.S. Healthcare Professionals Only <a href="#ISIarea">Read full Important Safety Information including Boxed WARNING</a></strong></p>
            </div>
          </div>
          <div class="col-lg-2 align-self-end">
            <div class="links">
              <a href="index.html" class="menu-link">Home</a>
            </div>
          </div>
        </div>
      </div>
    </div>
    <!-- Header End -->
    <!-- Slides Start -->
    <div class="slides owl-carousel" id="slides">
      <!--  Edetailer  Start -->
      <div class="single-slide">
        <div class="container">
          <div class="row">
            <div class="col-lg-12">
              <div class="title regular text-center text-uppercase">
                <h2>WHEN VULVAR AND VAGINAL ATROPHY (VVA) SYMPTOMS DISRUPT A PATIENT’S LIFE, IT COULD BE TIME FOR <strong>Osphena</strong><sup>®</sup></h2>
              </div>
            </div>
          </div>
          <div class="row align-items-center">
            <div class="col-lg-6">
              <div class="slides-text">
                <h4 class="secondary-title">FDA-approved, estrogen-free, locally acting Osphena<sup>®</sup><sup>1</sup></h4>
                <ul>
                  <li>The first and only SERM indicated for treatment of moderate to severe vaginal dryness and/or dyspareunia due to menopause</li>
                  <li>Estrogen-free</li>
                  <li>Exerts strong agonistic effect on vaginal tissue while exhibiting antagonistic or mild agonistic effects on other tissues</li>
                  <li>Convenient, oral administration</li>
                </ul>
                <p>Common side effects include hot flashes, vaginal discharge, muscle spasms, hyperhidrosis, night sweats, headaches and vaginal hemorrhage.</p>
                <p><small>SERM: selective estrogen receptor modulator </small></p>
                <a href="#slides" class="bordered-btn customNextBtn"><strong>Next</strong>: Learn about the impact of moderate to severe vaginal dryness and dyspareunia due to menopause</a>
              </div>
            </div>
            <div class="col-lg-6">
              <img src="assets/img/carousel-1.jpg" class="slide-right-img" alt="">
              <p><small>Not an actual patient</small></p>
            </div>
          </div>
        </div>
        <div class="subcription-area one">
          <div class="container">
            <div class="row justify-content-center">
              <div class="col-lg-5">
                <div class="subcription-box">
                  <h4>To receive resources and information 
                    about Bonjesta<sup>®</sup> enter your email here:
                  </h4>
                  <form action="#" class="infolettre" id="infolettre1">
                    <input type="email" name="email" class="form-control">
                    <span class="text-danger d-none champ-erreur">Required field</span><br>
                    <button class="white-btn" type="submit">Subscribe</button>
                  </form>
                  <div class="success-text">
                    <h2>Thank you for subscribing.</h2>
                  </div>
                </div>
                <a href="index.html" class="bordered-btn"><img src="assets/img/back.svg" alt=""> Back</a>
                <ul id='carousel-custom-dots' class='owl-dots'> 
                  <li class='owl-dot active'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                </ul>
              </div>
            </div>
          </div>
        </div>
        <div class="ref-area">
          <div class="container">
            <div class="row">
              <div class="col-lg-12">
                <h4>References</h4>
                <p>1.  Osphena Prescribing Information. January 2019.</p>
                <p>&nbsp;</p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!--  Edetailer  End -->
      <!--  Impact of Sikle Cell Disease  Start -->
      <div class="single-slide">
        <div class="container">
          <div class="row">
            <div class="col-lg-12">
              <div class="title regular text-center">
                <h2><strong>Osphena</strong><sup>®</sup> CAN HELP YOU ADDRESS 
                  YOUR PATIENTS’ NEEDS AND PREFERENCES</h2>
                <h3 class="secondary-title"><em>ABOUT VULVAR VAGINAL ATROPHY (VVA)</em><sup>1,2</sup></h3>
              </div>
            </div>
          </div>
          <div class="row align-items-center">
            <div class="col-lg-6">
              <div class="slides-text">
                <h4 class="secondary-title">MODERATE TO SEVERE VAGINAL DRYNESS AND DYSPAREUNIA ARE TWO OF THE MOST COMMON BOTHERSOME SYMPTOMS OF MENOPAUSE<sup>2,3</sup></h4>
                <p>Moderate to severe vaginal dryness and dyspareunia have a negative impact on women’s quality of life, psychosocial wellbeing and sexual function. These VVA symptoms  are often underdiagnosed and when treated, existing treatment options are unappealing to many women.</p>
                <br>
                <p>Did you know?</p>
                <div class="ribbon-box">
                  <div class="single-ribbon">
                    <img src="assets/img/79parcen.png" alt="">
                    <p>of menopausal women report vaginal dryness as a bothersome symptom of menopause.<sup>3</sup></p>
                  </div>
                  <div class="single-ribbon">
                    <img src="assets/img/59parcen.png" alt="">
                    <p>of menopausal women report dyspareunia as a bothersome symptom of menopause.<sup>3</sup></p>
                  </div>
                  <div class="single-ribbon">
                    <img src="assets/img/55parcen.png" alt="">
                    <p>of women expressed a preference for an oral product instead of a topical one.<sup>2</sup></p>
                  </div>
                </div>
                <h4 class="secondary-title"><em>VVA is an undertreated medical condition<sup>2</sup></em></h4>
                <p>Osphena<sup>®</sup> is contraindicated in patients with:<sup>1</sup></p>
                <ul>
                  <li>Undiagnosed abnormal genital bleeding.</li>
                  <li>Known or suspected estrogen-dependent neoplasia.</li>
                  <li>Active deep vein thrombosis (DVT), pulmonary embolism (PE), 
                    or a history of these conditions.</li>
                  <li>Active arterial thromboembolic disease (for example, stroke and myocardial infarction [MI]), or a history of these conditions.</li>
                  <li>Hypersensitivity (for example, angioedema, urticaria, rash, pruritus) to Osphena<sup>®</sup> or any of its ingredients.</li>
                  <li>Known or suspected pregnancy.</li>
                </ul>
                <a href="#slides" class="bordered-btn customNextBtn"><strong>Next</strong>: Learn about dosing</a>
              </div>
            </div>
            <div class="col-lg-6">
              <img src="assets/img/slide-2.png" class="slide-right-img" alt="">
              <p><small>Not an actual patient</small></p>
            </div>
          </div>
        </div>
        <div class="subcription-area two">
          <div class="container">
            <div class="row justify-content-center">
              <div class="col-lg-5">
                <div class="subcription-box">
                  <h4>To receive resources and information 
                    about Bonjesta<sup>®</sup> enter your email here:
                  </h4>
                  <form action="#" class="infolettre" id="infolettre2">
                    <input type="email" name="email" class="form-control">
                    <span class="text-danger d-none champ-erreur">Required field</span><br>
                    <button class="white-btn" type="submit">Subscribe</button>
                  </form>
                  <div class="success-text">
                    <h2>Thank you for subscribing.</h2>
                  </div>
                </div>
                <a href="#" class="bordered-btn customPrevBtn"><img src="assets/img/back.svg" alt=""> Back</a>
                <ul id='carousel-custom-dots' class='owl-dots'> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot active'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                </ul>
              </div>
            </div>
          </div>
        </div>
        <div class="ref-area">
          <div class="container">
            <div class="row">
              <div class="col-lg-12">
                <h4>References</h4>
                <p>1. Osphena Prescribing Information. January 2019.</p>
                <p>2.  Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10:1790–1799.</p>
                <p>3.  Kingsberg SA, Krychman M, et al. The Women’s EMPOWER Survey: Identifying Women’s Perceptions on Vulvar and Vaginal Atrophy and its Treatment. J Sex Med 2017; 14: 413-424.</p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!--  Impact of Sikle Cell Disease  End -->
      <!--  Impact of Sikle Cell Disease  Start -->
      <div class="single-slide">
        <div class="container">
          <div class="row">
            <div class="col-lg-12">
              <div class="title regular text-center">
                <h2><strong>Osphena</strong><sup>®</sup> is a daily medicatioN<sup>1</sup></h2>
              </div>
            </div>
          </div>
          <div class="row align-items-center">
            <div class="col-lg-6">
              <div class="slides-text">
                <h4 class="secondary-title">The <strong>only</strong> treatment for moderate to severe vaginal dryness and/or dyspareunia due to menopause, offered conveniently as an oral administration.</h4>
                  <p>How to take Osphena<sup>®</sup> </p>
                <div class="ribbon-box">
                  <div class="single-ribbon">
                    <img src="assets/img/1tablet.png" alt="">
                    <p>taken orally once daily with food </p>
                  </div>
                </div>
                <h4 class="secondary-title"><em>Osphena<sup>®</sup> should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.</em></h4>
                <a href="#slides" class="bordered-btn customNextBtn"><strong>Next</strong>: Learn about efficacy</a>
              </div>
            </div>
            <div class="col-lg-6">
              <img src="assets/img/slider-3.png" class="slide-right-img" alt="">
            </div>
          </div>
        </div>
        <div class="subcription-area three">
          <div class="container">
            <div class="row justify-content-center">
              <div class="col-lg-5">
                <div class="subcription-box">
                  <h4>To receive resources and information 
                    about Bonjesta<sup>®</sup> enter your email here:
                  </h4>
                  <form action="#" class="infolettre" id="infolettre3">
                    <input type="email" name="email" class="form-control">
                    <span class="text-danger d-none champ-erreur">Required field</span><br>
                    <button class="white-btn" type="submit">Subscribe</button>
                  </form>
                  <div class="success-text">
                    <h2>Thank you for subscribing.</h2>
                  </div>
                </div>
                <a href="#" class="bordered-btn customPrevBtn"><img src="assets/img/back.svg" alt=""> Back</a>
                <ul id='carousel-custom-dots' class='owl-dots'> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot active'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                </ul>
              </div>
            </div>
          </div>
        </div>
        <div class="ref-area">
          <div class="container">
            <div class="row">
              <div class="col-lg-12">
                <h4>References</h4>
                <p>1.  Osphena Prescribing Information. January 2019.</p>
                <br>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!--  Impact of Sikle Cell Disease  End -->
      <!--  Dissolvable Message Screen  Start -->
      <div class="single-slide">
        <div class="container">
          <div class="row">
            <div class="col-lg-12">
              <div class="title regular text-center">
                <h2><strong>OSPHENA</strong><sup>®</sup> IMPROVED SPECIFIC 
                  VAGINAL TISSUE IN JUST 12 WEEKS<sup>1</sup></h2>
              </div>
            </div>
          </div>
          <div class="row align-items-center">
            <div class="col-lg-6">
              <div class="slides-text">
                <h4 class="secondary-title text-uppercase">STATISTICALLY SIGNIFICANT RESULTS SEEN WITH Osphena<sup>®</sup><sup>1</sup></h4>
                <ul>
                  <li>Increase in the proportion of superficial cells (p&lt;0.0001)</li>
                  <li>Decrease in the proportion of parabasal cells (p&lt;0.0001)</li>
                  <li>Reduction in vaginal pH (p&lt;0.0001)</li>
                </ul>
                
                <h4 class="secondary-title text-uppercase"><em>Some patients saw results as early as week 4 (secondary endpoint)</em></h4>
                <p>By week 12:</p>
                <div class="ribbon-box">
                  <div class="single-ribbon">
                    <img src="assets/img/2x.png" alt="">
                    <p>as many Osphena<sup>®</sup> patients saw improvements in vaginal dryness vs. placebo (odds ratio 2.23, 95% CI: 1.62–3.06)<sup>2†</sup></p>
                  </div>
                  <div class="single-ribbon">
                    <img src="assets/img/5x.png" alt="">
                    <p>as many Osphena<sup>®</sup> patients responded to therapy vs. placebo (31.5% vs. 6.0%; p&lt;0.0001)<sup>2¶</sup></p>
                  </div>
                </div>
                <p>Common side effects include: Hot flashes, vaginal discharge, muscle spasms, hyperhidrosis, night sweats, headaches and vaginal hemorrhage<sup>1</sup></p>
                <p>Study design: Three 12-week, randomized, double-blind, placebo-controlled, parallel group studies in post menopausal women</p>
                <p>†Women who reported moderate or severe vaginal dryness as their most bothersome symptom, who had 5% or lesser superficial cells on their vaginal wall smear and a vaginal pH of more than 5.0 were eligible to participate.</p>

                <p>¶Responders defined as those with improvements from baseline in the maturation value of 10 points, in vaginal pH of 0.5, and in the most bothersome symptom of vaginal dryness of 1 point.</p>
                <a href="#slides" class="bordered-btn customNextBtn"><strong>Next</strong>: Learn about the safety of Osphena<sup>®</sup></a>
              </div>
            </div>
            <div class="col-lg-6">
              <img src="assets/img/slider-4.jpg" class="slide-right-img" alt="">
            </div>
          </div>
        </div>
        <div class="subcription-area four">
          <div class="container">
            <div class="row justify-content-center">
              <div class="col-lg-5">
                <div class="subcription-box">
                  <h4>To receive resources and information 
                    about Bonjesta<sup>®</sup> enter your email here:
                  </h4>
                  <form action="#" class="infolettre" id="infolettre4">
                    <input type="email" name="email" class="form-control">
                    <span class="text-danger d-none champ-erreur">Required field</span><br>
                    <button class="white-btn" type="submit">Subscribe</button>
                  </form>
                  <div class="success-text">
                    <h2>Thank you for subscribing.</h2>
                  </div>
                </div>
                <a href="#" class="bordered-btn customPrevBtn"><img src="assets/img/back.svg" alt=""> Back</a>
                <ul id='carousel-custom-dots' class='owl-dots'> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot active'></li> 
                  <li class='owl-dot'></li> 
                </ul>
              </div>
            </div>
          </div>
        </div>
        <div class="ref-area">
          <div class="container">
            <div class="row">
              <div class="col-lg-12">
                <h4>References</h4>
                <p>1.  Osphena Prescribing Information. January 2019.</p>
                <p>2.  Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621.</p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!--  Dissolvable Message Screen  End -->
      <!-- Efficacy Message Screen Start -->
      <div class="single-slide">
        <div class="container">
          <div class="row">
            <div class="col-lg-12">
              <div class="title regular text-center">
                <h2><strong>Osphena</strong><sup>®</sup>: proven safety in ten phase 2/3 trials<sup>1</sup>
                </h2>
              </div>
            </div>
          </div>
          <div class="row align-items-center">
            <div class="col-lg-6">
              <div class="slides-text">
                <h4 class="secondary-title">About the clinical trials</h4>
                <div class="ribbon-box">
                  <div class="single-ribbon">
                    <img src="assets/img/10.png" alt="">
                    <p>phase 2/3 clinical trials</p>
                  </div>
                  <div class="single-ribbon">
                    <img src="assets/img/upto52.png" alt="">
                    <p>weeks of duration</p>
                  </div>
                  <div class="single-ribbon">
                    <img src="assets/img/2209.png" alt="">
                    <p>Largest population of postmenopausal women with moderate to severe vaginal dryness and dyspareunia1,2</p>
                  </div>
                </div>
                <p>Common side effects include: Hot flashes, vaginal discharge, muscle spasms, hyperhidrosis, night sweats, headaches and vaginal hemorrhage<sup>1</sup></p>
                <h4 class="secondary-title">Osphena<sup>®</sup> IS A SERM, NOT AN ESTROGEN<sup>1,5,7</sup></h4>
                <ul>
                  <li>Acts selectively as an estrogen receptor agonist on the vagina<sup>1,4,8</sup></li>
                  <li>Acts locally as a function of its characteristic tissue selectivity<sup>4,8</sup></li>
                </ul>
              </div>
            </div>
            <div class="col-lg-6">
              <img src="assets/img/slider-5.jpg" class="slide-right-img" alt="">
              <!-- <p><small>Not an actual patient</small></p> -->
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12">
              <div id="accordion">
                <div class="card">
                  <div class="card-header" id="headingOne">
                    <h5 class="mb-0">
                      <button class="collapsed" data-toggle="collapse" data-target="#collapseOne" aria-expanded="false" aria-controls="collapseOne">
                        Breast safety considerations <img src="assets/img/plus.svg" alt="">
                      </button>
                    </h5>
                  </div>
              
                  <div id="collapseOne" class="collapse" aria-labelledby="headingOne" data-parent="#accordion">
                    <div class="card-body">
                      <h4 class="green">Breast safety considerations<sup>2,3</sup></h4>
                      <p>Phase 2/3 clinical studies of Osphena<sup>®</sup> 60 mg, which included postmenopausal women (aged 40-80 years) with VVA.<sup>2,3</sup></p>
                      <ul>
                        <li>Patients had to have a normal clinical breast examination at screening.*</li>
                        <li>Patients underwent a full breast examination at screening and had follow-up assessments at 12 weeks, 6 months, and 12 months.</li>
                      </ul>
                      <p>These studies demonstrated the following:<sup>2,3,5</sup></p>
                      <ul>
                        <li>No clinically significant mammographic changes in Osphena<sup>®</sup>-treated patients.</li>
                        <li>A decrease in abnormal breast palpation findings from baseline to 52 weeks:
                          <ul>
                            <li>Osphena<sup>®</sup>: 2.8% at baseline (N=1102) vs. 0.8% at 52 weeks (N=354).</li>
                            <li>Placebo: 2.3% at baseline (N=821) vs. 0% at 52 weeks (N=90).</li>
                          </ul>
                        </li>
                        <li>A low rate of breast-related treatment-related adverse events (2.1% Osphena<sup>®</sup> [33/1559] vs. 1.6% placebo [21/1268]).</li>
                        <li>No cases of breast cancer in the Osphena<sup>®</sup> group (0% vs. 0.2% [2/1268] placebo†).</li>
                      </ul>
                      <p>Osphena<sup>®</sup> has not been adequately studied in women with breast cancer, therefore, it should not be used in women with known or suspected breast cancer.</p>
                      <p><small>
                        * Obtained at screening or within 9 months prior to randomization.<br/>
                        † Including one case of breast cancer, in situ.
                      </small></p>
                    </div>
                  </div>
                </div>
                <div class="card">
                  <div class="card-header" id="headingTwo">
                    <h5 class="mb-0">
                      <button class="collapsed" data-toggle="collapse" data-target="#collapseTwo" aria-expanded="false" aria-controls="collapseTwo">
                        Cardiovascular data <img src="assets/img/plus.svg" alt="">
                      </button>
                    </h5>
                  </div>
                  <div id="collapseTwo" class="collapse" aria-labelledby="headingTwo" data-parent="#accordion">
                    <div class="card-body">
                      <h4 class="green">Cardiovascular (cv) data<sup>1</sup></h4>
                      <p>In clinical trials, less than 1% of patients experienced treatment-related CV events.<sup>1</sup></p>

                      <p>Phase 2/3 clinical studies of Osphena<sup>®</sup> 60 mg, which included postmenopausal women (aged 40–80 years) with VVA, demonstrated the following:<sup>1,5,6</sup></p>
                      <img src="assets/img/adverse_events_graph.png" alt="">
                      <p>Osphena<sup>®</sup> has a boxed warning regarding endometrial cancer and cardiovascular disorders.</p>
                    </div>
                  </div>
                </div>
              </div>
              
              <a href="#slides" class="bordered-btn customNextBtn"><strong>Next</strong>: Learn about the cost and coverage of Osphena<sup>®</sup></a>
            </div>
          </div>
        </div>
        <div class="subcription-area five">
          <div class="container">
            <div class="row justify-content-center">
              <div class="col-lg-5">
                <div class="subcription-box">
                  <h4>To receive resources and information 
                    about Bonjesta<sup>®</sup> enter your email here:
                  </h4>
                  <form action="#" class="infolettre" id="infolettre5">
                    <input type="email" name="email" class="form-control">
                    <span class="text-danger d-none champ-erreur">Required field</span><br>
                    <button class="white-btn" type="submit">Subscribe</button>
                  </form>
                  <div class="success-text">
                    <h2>Thank you for subscribing.</h2>
                  </div>
                </div>
                <a href="#" class="bordered-btn customPrevBtn"><img src="assets/img/back.svg" alt=""> Back</a>
                <ul id='carousel-custom-dots' class='owl-dots'> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot active'></li> 
                </ul>
              </div>
            </div>
          </div>
        </div>
        <div class="ref-area">
          <div class="container">
            <div class="row">
              <div class="col-lg-12">
                <h4>References</h4>
                <p>1.  Osphena Prescribing Information. January 2019.</p>
                  
                <p>2.  Data on file. Duchesnay USA Inc.</p> 
                  
                <p>3.  Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Women’s Health. 2018;27(1):14–23. </p>
                  
                <p>4.  Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an International Menopause Society White Paper. Climacteric. 2018;21(5):415-427.</p>
                <p>5.  Archer DF, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611–621.</p>
                <p>6.  Constantine G et al. Endometrial safety of ospemifene: results of the Phase 2/3 clinical development program. Menopause. 2015;1(22):36‐43. </p>

                <p>7.  Pinkerton JV, Thomas S. J Steroid Biochem Mol Biol. 2014;142:142-154. </p>
                  
                <p>8.  Archer DF, Carr BR, Pinkerton JV, et al. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause. 2015;22(7):786–796. </p>
              </div>
            </div>
          </div>
        </div>
      </div>

      <div class="single-slide">
        <div class="container">
          <div class="row">
            <div class="col-lg-12">
              <div class="title regular text-center">
                <h2>There are several ways for patients  to save on <strong>Osphena</strong><sup>®</sup></h2>
              </div>
            </div>
          </div>
          <div class="row align-items-center">
            <div class="col-lg-6">
              <div class="slides-text">
                <h4 class="secondary-title">Osphena<sup>®</sup> CoPay Savings Card</h4>
                <p>With the Osphena<sup>®</sup> CoPay Savings Card, patients without prescription commercial insurance or whose insurance does not cover Osphena<sup>®</sup> may pay as little as $75 for 30 tablets or $190 for 90 tablets through a retail pharmacy.</p>

                <p>Terms and Conditions apply. Please see <a href="http://hcp.osphena.com" target="_blank" rel="noopener noreferrer">hcp.osphena.com</a><span class="red inline"><em>For more information, please call 1-866-339-0316</em> <img src="assets/img/phone.svg" alt=""></span></p>
                
                <h4 class="secondary-title">Osphena At home<sup>®</sup></h4>
                <p>Pay as little as $75 for 30 tablets or $190 for 90 tablets and receive free home delivery, on-staff pharmacists to answer product questions, assistance with insurance benefit verification and monthly refill reminders.</p>
                <p><span class="red inline">For more information, please call (844) 716-HOME (4663) <img src="assets/img/phone.svg" alt=""></span></p>
              </div>
            </div>
            <div class="col-lg-6">
              <img src="assets/img/slider-6.png" class="slide-right-img" alt="">
              <!-- <p><small>Not an actual patient</small></p> -->
            </div>
          </div>
        </div>
        <div class="subcription-area six">
          <div class="container">
            <div class="row justify-content-center  pb-5">
              <div class="col-lg-5 pb-5 mb-5">
                <div class="subcription-box">
                  <h4>To receive resources and information 
                    about Bonjesta<sup>®</sup> enter your email here:
                  </h4>
                  <form action="#" class="infolettre" id="infolettre5">
                    <input type="email" name="email" class="form-control">
                    <span class="text-danger d-none champ-erreur">Required field</span><br>
                    <button class="white-btn" type="submit">Subscribe</button>
                  </form>
                  <div class="success-text">
                    <h2>Thank you for subscribing.</h2>
                  </div>
                </div>
                <a href="#" class="bordered-btn customPrevBtn"><img src="assets/img/back.svg" alt=""> Back</a>
                <ul id='carousel-custom-dots' class='owl-dots'> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot'></li> 
                  <li class='owl-dot active'></li> 
                </ul>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!--  Efficacy Message Screen  End -->
    </div>
    <!-- Slides End -->
    <!-- Landing Wrapper End -->
    <div class="isi sticky" id="fixedISI">
      <div class="container">
        <a href="#ISIarea" role="button" class="expand-isi"></a>
        <!-- ISI -->
        <div class="moduletable">
          <div class="custom">
            <!-- START: Articles Anywhere -->
            <div class="article-14">
              <h2>INDICATION AND IMPORTANT SAFETY INFORMATION</h2>
              <div class="row">
                <div class="col-xs-12 col-sm-4 col-md-3">
                  <h3>INDICATION:</h3>
                  <p>OSPHENA&nbsp;(ospemifene) is indicated for:</p>
                  <ul>
                    <li>The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause</li>
                    <li>The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause</li>
                  </ul>
                </div>
                <div class="col-xs-12 col-sm-8 col-md-9">
                  <h3>Important Safety Information for OSPHENA</h3>
                  <div class="panel panel-default">
                    <div class="panel-body">
                      <h4>WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS</h4>
                      <p>Endometrial Cancer</p>
                      <p>OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.</p>
                      <p>Cardiovascular Disorders</p>
                      <p>In clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively, in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.</p>
                      <p>There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative (WHI).</p>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <!-- END: Articles Anywhere -->
          </div>
        </div>
        <!-- //ISI -->
      </div>
    </div>
    <div class="indication-area isi" id="ISIarea">
      <div class="container">
        <!-- ISI -->
        <div class="moduletable">
          <div class="custom">
            <div class="article=15">
              <!-- START: Articles Anywhere -->
              <h2 class="text-uppercase">Indication and Important Safety Information including Boxed Warning</h2>
              <h3>INDICATION:</h3>
              <p>OSPHENA (ospemifene) is indicated for:</p>
              <ul>
                <li>The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.</li>
                <li>The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.</li>
              </ul>
              <h3>Important Safety Information for OSPHENA</h3>
              <!-- END: Articles Anywhere -->
              <div class="panel panel-default">
                <!-- START: Articles Anywhere -->
                <div class="panel-body article-16">
                  <h4>WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS</h4>
                  <p>Endometrial Cancer</p>
                  <p>OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.</p>
                  <p>Cardiovascular Disorders</p>
                  <p>In clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively, in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.</p>
                  <p>There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative (WHI).</p>
                </div>
                <!-- END: Articles Anywhere -->
              </div>
              <!-- START: Articles Anywhere -->
              <div class="article-17">
                <h3>CONTRAINDICATIONS</h3>
                <ul>
                  <li>Undiagnosed abnormal genital bleeding</li>
                  <li>Known or suspected estrogen-dependent neoplasia</li>
                  <li>Active deep vein thrombosis (DVT), pulmonary embolism (PE) or a history of these conditions</li>
                  <li>Active arterial thromboembolic disease (e.g., stroke and myocardial infarction) or a history of these conditions</li>
                  <li>Hypersensitivity (for example, angioedema, urticaria, rash, pruritus) to OSPHENA or any of its ingredients</li>
                  <li>OSPHENA is contraindicated in women who are or may become pregnant. OSPHENA may cause fetal harm when administered to a pregnant woman. Ospemifene was embryo-fetal lethal with labor difficulties and increased pup deaths in rats at doses below clinical exposures, and embryo-fetal lethal in rabbits at 10 times the clinical exposure based on mg/m. If this drug is used during pregnancy, or if a woman becomes pregnant while taking this drug, she should be apprised of the potential hazard to a fetus.</li>
                </ul>
                <h3>WARNINGS AND PRECAUTIONS</h3>
                <h4>Cardiovascular Disorders</h4>
                <p>In the clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively in OSPHENA 60 mg treatment group and 3.15 and 0 per thousand women years in placebo. Should thromboembolic or hemorrhagic stroke occur or be suspected, OSPHENA should be discontinued immediately.</p>
                <p>In the OSPHENA clinical trials, two cases of myocardial infarctions (MI) occurred in women receiving 60 mg of ospemifene.</p>
                <p>In the OSPHENA clinical trials, two cases of DVT occurred in women receiving OSPHENA 60 mg. Should a VTE occur or be suspected, OSPHENA should be discontinued immediately.</p>
                <p>If feasible, OSPHENA should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
                <h4>Malignant Neoplasms</h4>
                <p>OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has agonistic effects. In the OSPHENA clinical trials (60 mg treatment group), no cases of endometrial cancer were seen with exposure up to 52 weeks. There was a single case of simple hyperplasia without atypia. Endometrial thickening equal to 5 mm or greater was seen in the OSPHENA up to 52 weeks treatment groups at a rate of 101.4 per thousand women vs. 20.9 per thousand women for placebo. The incidence of any type of proliferative (weakly plus active plus disordered) endometrium was 26.3 per thousand women in the OSPHENA up to 52 weeks treatment groups vs. 0 per thousand women for placebo. Uterine polyps occurred at an incidence of 19.6 per thousand women in the OSPHENA up to 52 weeks treatment groups vs. 8.3 per thousand women for placebo.</p>
                <p>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The greatest risk appears to be associated with prolonged use and estrogen dose. Adding a progestin to postmenopausal estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. The use of with OSPHENA therapy was not evaluated in the clinical trials.</p>
                <p>OSPHENA 60 mg has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer.</p>
                <h4>Severe Hepatic Impairment</h4>
                <p>OSPHENA should not be used in women with severe hepatic impairment.</p>
                <p><strong>In clinical trials, the more commonly reported adverse reactions</strong> in ≥1 percent of patients treated with OSPHENA 60 mg compared to placebo were:</p>
                <ol>
                  <li>In 12-week, double blind, placebo-controlled clinical trials were hot flush (6.5% vs. 2.6%), vaginal discharge (3.8% vs. 0.4%), muscle spasms (1.8% vs. 0.6%) and hyperhidrosis (1.1% vs. 0.2%)</li>
                  <li>In all clinical trials up to 52-weeks (safety population) were headaches (2.8% vs. 2.4%), hot flush (12.2% vs. 4.2%), muscle spasms (4.5% vs. 2.4%), hyperhidrosis (2.5% vs. 1.8%), night sweats (1.2% vs. 0.0%), vaginal discharge (6.00% vs. 0.6%) and vaginal hemorrhage (1.3% vs. 0.0%).</li>
                </ol>
                <p>The following adverse reactions have been identified during post-approval use of ospemifene:</p>
                <ul>
                  <li>Neoplasms Benign, Malignant and Unspecified (including cysts and polyps); endometrial hyperplasia, endometrial cancer.</li>
                  <li>Immune System Disorders: allergic conditions including hypersensitivity, angioedema</li>
                  <li>Nervous System Disorders: headache</li>
                  <li>Vascular Disorders: deep vein thrombosis, thrombosis, pulmonary embolism</li>
                  <li>Skin and Subcutaneous Tissue Disorders: rash, rash erythematous, rash generalized, pruritus, urticaria</li>
                </ul>
                <p><strong>Drug interactions:</strong> OSPHENA is primarily metabolized by CYP3A4 and CYP2C9. CYP2C19 and other pathways contribute to the metabolism of ospemifene. Do not use estrogens or estrogen agonists/antagonists, fluconazole, ketoconazole or rifampin concomitantly with OSPHENA. Co-administration of OSPHENA with drugs that inhibit CYP3A4 and CYP2C9 may increase the risk of OSPHENA-related adverse reactions. OSPHENA is highly protein bound. Use cautiously with highly protein bound drugs as use with other highly protein-bound drugs may lead to increase exposure of that drug or ospemifene.</p>
                <p>Please see <strong><a href="https://files.duchesnay.com/duchesnay-usa/osphena/osphena-prescribing-information.pdf" target="_blank" rel="noopener">Full Prescribing Information</a></strong> for OSPHENA (ospemifene) tablets, including <strong>Boxed Warning</strong>, regarding Endometrial Cancer and Cardiovascular Disorders, and <a href="https://files.duchesnay.com/duchesnay-usa/osphena/osphena-patient-information.pdf" target="_blank" rel="noopener"><strong>Patient Information</strong></a> at <a href="https://hcp.osphena.com/">osphena.com/hcp</a>.</p>
              </div>
              <!-- END: Articles Anywhere -->
            </div>
          </div>
        </div>
        <!-- //ISI -->
      </div>
    </div>
    <!-- Footer start -->
    <footer id="t3-footer" class="wrap t3-footer">
      <div class="container">
        <div class="row">
          <div class="col-xs-12 col-sm-3 logo">
            <img class="logo-img" src="assets/img/osphena-logo-white.svg" alt="Osphena HCP">
            <div class="custom-linkedin">
              <div><a title="Linkedin Duchesnay USA" href="https://www.linkedin.com/company/info-duchesnayusa-com" target="_blank" rel="noopener"><img src="assets/img/linkedin.png" alt=""></a></div>
            </div>
          </div>
          <div class="col-xs-12 col-sm-4 menu">
            <ul class="nav nav-pills nav-stacked menu">
              <li class="item-112"><a href="https://www.duchesnayusa.com/en/contact-us" class="" target="_blank" rel="noopener noreferrer">Contact Us </a></li>
              <li class="item-113"><a href="https://files.duchesnay.com/duchesnay-usa/osphena/osphena-patient-information.pdf" class="" target="_blank" rel="noopener noreferrer">Patient Information </a></li>
              <li class="item-114"><a href="https://files.duchesnay.com/duchesnay-usa/osphena/osphena-prescribing-information.pdf" class="" target="_blank" rel="noopener noreferrer">Prescribing Information </a></li>
              <li class="item-115"><a href="https://www.duchesnayusa.com/en/legal/privacy" class="" target="_blank" rel="noopener noreferrer">Privacy Policy </a></li>
              <li class="item-116"><a href="https://www.duchesnayusa.com/en/legal/termsofuse" class="" target="_blank" rel="noopener noreferrer">Terms of Use </a></li>
            </ul>
          </div>
          <div class="col-xs-12 col-sm-5 others">
            <div class="custom-customerservice">
              <div>
                <p>Osphena Customer Service</p>
                <div class="row box-white">
                  <div class="col-xs-12 col-sm-6"><a href="tel:1-855-677-4362">1-855-677-4362</a></div>
                  <div class="col-xs-12 col-sm-6"><a href="mailto:customerservice@duchesnayusa.com">Write to us</a></div>
                </div>
              </div>
            </div>
            <div class="custom-copyright">
              <p>©&nbsp;2021 Duchesnay USA Inc. All Rights Reserved. Osphena<sup>®</sup> is a registered trademark of Duchesnay USA, Pennsylvania, USA.</p>
              <p>For US residents only.</p>
            </div>
            <div class="custom-mlr">
              <div class="article-76">
                <p>OSP-2019-0029-10 Feb 2021</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </footer>
    <!-- Footer end -->
    <!-- jQuery library -->
    <script src="assets/js/jquery-3.5.1.min.js"></script>
    <!-- Popper js -->
    <script src="assets/js/popper.min.js"></script>
    <!-- Bootsrap js -->
    <script src="assets/js/bootstrap.min.js"></script>
    <!-- owl js -->
    <script src="assets/js/owl.carousel.min.js"></script>
    <!-- Main js -->
    <script src="assets/js/main.js"></script>
  </body>
</html>